Needham & Company
-
Needham & Company Reiterates Apellis Pharmaceuticals (APLS) at Buy, $70 PT, "Data Bode Well for Approval in GA"
-
Apellis Pharmaceuticals (APLS) Stock Named Top Pick at Needham, Analyst Sees Over 45% Upside
-
Needham & Company Adds Apellis Pharmaceuticals (APLS) to Conviction List, Calls Top Pick for 2022
-
Apellis Pharmaceuticals (APLS) PT Lowered to $70 at Needham & Company
-
Apellis Pharmaceuticals (APLS) PT Raised to $85 at Needham & Company After Previewing Phase 3 DERBY/OAKS Readout
-
Apellis Pharmaceuticals (APLS) PT Raised to $65 at Needham & Company
-
Pre-Open Movers 04/17: (RNDA) (ROKU) (NFLX) Higher; (BLCM) (LADR) (SEAC) Lower (more...)